Navigation Links
Quercegen Pharmaceuticals LLC Obtains FDA GRAS Notified Status for its QU995™ Quercetin with Purity Greater than 99.5%
Date:2/3/2011

industry, a new food ingredient needs to be shown to be Generally Regarded As Safe (GRAS). In addition, the FDA will not consider an ingredient for a health claim (substantiated or qualified) if the ingredient has not been demonstrated to be GRAS.

After years of research and work in collaboration with Merck Natural Products, commercial partners and various United States government agencies, Quercegen is introducing its first branded product, Q-Force™ (www.qforce.com) to the U.S. and European markets. Together with DARPA (the U.S. Defense Advanced Research Projects Agency) and Nutravail Technologies, the Company developed Q-Force™ soft chews, which have been sold mainly to military personnel since 2007 and are now scheduled for a broader consumer rollout in 2011. Q-Force™ will be promoted towards active consumers seeking enhanced performance and overall health.  

"DARPA researchers have identified a very safe, natural antioxidant – called Quercetin – and developed it into a new form that is now available to the military and the general public. Among Quercetin's many potential benefits is illness prevention. In a randomized, placebo-controlled study, Quercetin helped prevent viral illnesses, like colds and flu, after physical exertion. Following a strenuous 3-day exercise routine, 50 percent of the control group became ill with colds and flu, whereas only five percent of the Quercetin supplemented group did. This important immune protective effect will help keep our warfighters healthy during training and deployment. Quercetin has been commercialized as RealFX Q-Plus™* soft chews, which are now available through several commercial vendors, as well as to all military personnel at a 50 percent discount."

--Dr. Tony Tether, Director, Defense Advanced Research Projects Agency Testimony Submitted to the Subcommittee on Terrorism, Unconventional Threats and Capabilities, Hous
'/>"/>

SOURCE Quercegen Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free ... ), Eli Lilly and Company (NYSE: LLY - Free ... and InterMune, Inc. (Nasdaq: ITMN - Free Report ). ...
(Date:7/21/2014)... , July 21, 2014   Regulus ... biopharmaceutical company leading the discovery and development of ... U.S. Food & Drug Administration (FDA) has granted ... chemically modified oligonucleotide that binds to and inhibits ... for the treatment of Alport syndrome, a life-threatening ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Feb. 8, 2011 DURECT Corporation (Nasdaq: ... has launched commercial sales of its Food and Drug ... injectable animal health drug utilizing DURECT,s SABER™ technology to ... on net sales of SucroMate and will supply one ...
... DIEGO, Feb. 8, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the 13th Annual Bio CEO & Investor Conference on Tuesday, ...  The conference is being held at the Waldorf-Astoria Hotel in ... Officer of Anadys, will provide an overview of Anadys and ...
Cached Medicine Technology:DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 2DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product 3Anadys Pharmaceuticals to Present at the Bio CEO & Investor Conference 2
(Date:7/21/2014)... for Public Affairs Research has released the results of ... it means to be a quality health care provider ... Robert Wood Johnson Foundation, sheds new light on how ... and doctors, as well as the information they use ... produces new and actionable data during a crucial period ...
(Date:7/21/2014)... Western University of Health Sciences ... For” by the Chronicle of Higher Education for ... Honor Roll for the first time. , WesternU ... and Benefits, Confidence in Senior Leadership, Job Satisfaction, ... “Western University of Health Sciences is a great ...
(Date:7/21/2014)... -- Good parenting and life skills coaching seem ... a new study suggests. Inflammation is a ... to a number of illnesses, according to Northwestern ... childhood and adulthood involve excessive inflammation. The process ... and some cancers," study author Gregory Miller, a ...
(Date:7/21/2014)... A new study suggests that potential help in ... your refrigerator. The study found that regular intake ... or supplements, may help ease the condition. Researchers ... between probiotics and blood pressure. The studies involved a ... blood pressure. People who consumed probiotics had an ...
(Date:7/21/2014)... may be getting women to go to the hospital more ... shows women have longer hospital stays and are more likely ... attack. , In the study published online today in the ... from Yale School of Medicine analyzed 230,684 hospitalizations for heart ... of 1.1 million hospitalizations reported in a national database from ...
Breaking Medicine News(10 mins):Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
... to Cover Medical Devices, ARLINGTON, Va., Nov. 2 ... Capital Markets) today announced that,Christopher Warren has joined FBR ... Analyst within its healthcare group and will,focus on the ... of experience in equity research, and we,value the disciplined, ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... offer convertible senior notes. The decision not to ... due principally to prevailing,market conditions resulting in note ... Note Regarding Forward-Looking Statements This release contains ...
... Pa., Nov. 2 Kensey Nash Corporation,(Nasdaq: ... licensed U.S. patent,6,175,669, Optical Coherence Domain Reflectometry Guidewire, ... the intellectual,property portfolio related to its chronic total ... enhanced optical sensing capabilities,allowing it to sense locations, ...
... Just how much of the time,that sales people should be ... internal communication? Pharmaceutical sales directors agree the answer is ... for internal communication - or 6 weeks per rep,per year ... year,according to a recent research study by Best Practices, LLC. ...
... inhibitor demonstrates >99% mean decrease in HCV RNA ... with no serious adverse events-, ... the results of a 14-day Phase 1 multiple ascending,dose monotherapy study ... study, being presented as a "late-breaker" abstract at,the 58th Annual Meeting ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) will announce ... 8, 2007, after market close. The announcement ... followed by a conference call and live webcast ... 4:30 p.m. Eastern. Interested parties may access the,live ...
Cached Medicine News:Health News:FBR Capital Markets Hires Senior Healthcare Analyst 2Health News:Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 2Health News:Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform 3Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 2Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 3Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 4Health News:Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C 5Health News:Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results 2
... Apron has standard front protection. ... from the shoulders to the ... a 6" wide elastic belt. ... apron snug. Belts may be ...
... new Breast Overlay Apron ... provide extra coverage for ... adjustable velcro flaps allow ... fit, plust added coverage ...
Lap pad used to protect pelvic regions...
... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
Medicine Products: